Navigation Links
74 Percent EBITDA Improvement at Zeltia Group in 2010
Date:2/24/2011

MADRID, Feb. 24, 2011 /PRNewswire/ -- Zeltia Group's net revenues totaled 153.5 million euro in 2010 (approximately 211.4 million USD*), 24.4 percent more than in 2009 (123.4 million euro, or approximately 169.9 million USD). This performance is primarily attributable to a 70 percent increase in Yondelis® sales.

Net sales in the Biopharmaceutical business amounted to 79.4 million euro (approximately 109.3 million USD) in 2010 (51.1 million euro, or approximately 70.3 million USD in 2009), of which 72.1 million (approximately 99.3 million USD) correspond to Yondelis® (43.8 million euro, or approximately 60.3 million USD in 2009).

The Biopharmaceutical segment accounted for 52 percent of total Group revenues in 2010, exceeding for the first time the contribution from the Consumer Chemicals business (73.2 million euro, or approximately 100.8 million USD in 2010, compared with 71.1 million euro, or approximately 97.9 million USD in 2009).

EBITDA improved by 74 percent in 2010 to -3.9 million euro (approximately -5.3 million USD) (-15.3 million euro or approximately -21.0 million USD in 2009).

Net income attributable to the parent company rose 71 percent with respect to 2009.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova an
'/>"/>

SOURCE Zeltia
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. 34 percent of Galician secondary schools exceed maximum recommended radon levels
2. 34 percent of Galician secondary schools exceed maximum recommended radon levels
3. Codexis Grows Revenue 35 Percent in Third Quarter; Raises 2010 Outlook
4. ReVisions Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial
5. Tecnalia investigates ecological cement that cuts CO2 emissions by up to 100 percent
6. ClearTrial to Demonstrate How a Top 20 Sponsor Achieved -1 Percent Cost Variance Across Their $130M Clinical Portfolio at Major Industry Conference
7. In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market
8. ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line
9. Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 Diabetes
10. New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials
11. Nearly 70 Percent of Health Professionals Support Biotechnologys Use in Food Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... As the weather warms, women everywhere are waiting for the ... make a statement with fashion, many change their makeup to ... mixes makeup and sweat to produce, and increase acne breakouts. ... warmer months, Adult Acne treatment , Probiotic Action shares ... to deter breakouts. , Recently, an article from ...
(Date:5/16/2013)... NEW YORK , May 16, ... a new market research report is ...   Competitor Analysis: ... Biosuperiors http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical ...   The ...
(Date:5/16/2013)... BioInformatics LLC New Market Report – ... Current and Future Opportunities (13-004) , With barriers ... primary cells market continues to increase. In this study, ... often, how satisfied scientists are with commercially available primary ... rate. ,  , Additionally, terminally differentiated cells can ...
(Date:5/16/2013)... 2013 Dr. Stephen Y. Chou, Founder ... “Nanoimprint Lithography and Applications” at IEEE Nano 2013 in ... in 1995 by Chou, is becoming one of the ... combination of sub-10 nm resolution, large area, and low ... both R&D and manufacturing in a broad range of ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3Founder, Prof. Stephen Chou to Give Tutorial on Nanoimprint at IEEE Nano 2013 2
... FRANKLIN LAKES, N.J., March 27 BD (Becton,Dickinson ... global medical technology,company, and Direct Relief International, a ... joint volunteer,initiative to strengthen healthcare in Ghana. A ... to Ghana for three weeks and work side-by-side,with ...
... Siemens Will Showcase Its Portfolio of Cardiovascular ... Healthcare, (http://www.usa.siemens.com/healthcare ) will demonstrate how its ... are helping,to "Bring a New Rhythm to ... of the American College of Cardiology (ACC) ...
... Aimed at Developing New Screening Methods and Holds Significant, Potential for Early ... ... Killer, - Biomarker Project holds significant potential for new screening ... the disease before even the ...
Cached Biology Technology:BD and Direct Relief International Launch Second Volunteer Service Trip to Improve Healthcare in Ghana 2BD and Direct Relief International Launch Second Volunteer Service Trip to Improve Healthcare in Ghana 3Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiology's Toughest Questions 2Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiology's Toughest Questions 3Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiology's Toughest Questions 4Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiology's Toughest Questions 5Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project 2Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project 3
(Date:5/16/2013)... years old give unprecedented insight into the evolutionary ... most species-rich groups among the modern bony fishes. ... from the Division of Paleontology and Geobiology at ... Ludwig-Maximilians-Universitaet (LMU) in Munich / Germany have completed ... assign to the group of bony fishes that ...
(Date:5/16/2013)... in Cameroon and the manager of San Diego Zoo ... prestigious Whitley award. The Whitley award is an ... because it celebrates the extraordinary achievements of some of ... Abwe was selected for the award due to his ... and its wildlife inhabitants., HRH The Princess Royal, the ...
(Date:5/15/2013)... in moderating gout risk, new research reveals that vitamin ... acid (urate) levels to a clinically significant degree in ... in combination with allopurinol, appears to have a weak ... according to the results published in the American College ... , Gout is an inflammatory arthritis that causes ...
Breaking Biology News(10 mins):Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Vitamin C does not lower uric acid levels in gout patients 2
... Nov. 1, 2011Researchers at St. Michael,s Hospital have identified ... They also identified two possible treatments to prevent ... the development of new drugs to treat heart attacks ... Ni, found that the same kind of blood-clotting in ...
... people can exchange information instantaneously in the digital age, ... freely and rapidly exchange genetic material related to human ... gene transfer (HGT). In a paper appearing in ... by Eric Alm of MIT,s Department of Civil and ...
... Chinese Academy of Sciences found one new species, Aleurodaphis sinojackiae ... forms leaf galls on Jack trees ( Sinojackia xylocarpa ) and is ... ( Hemiptera , Aphididae , Hormaphidinae ). The ... . Aleurodaphis was established in 1917 by van der ...
Cached Biology News:Researchers pinpoint possible new cause for unexplained miscarriages 2MIT: Bacteria may readily swap beneficial genes 2MIT: Bacteria may readily swap beneficial genes 3